EPRSQ EPIRUS Biopharmaceuticals Inc (CE)

EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced it will release its third quarter 2015 financial results on Thursday, November 12, 2015.  In conjunction with the release, the Company has scheduled a conference call and webcast on Thursday, November 12, 2015 at 8:00 a.m. ET to discuss the financial results and provide a business update.

Conference Call InformationWhen: Thursday, November 12, 2015, 8:00 a.m. ETDial-in: 1-855-638-3957 (United States) or 1-224-633-1318 (International)Conference ID: 67401555 Webcast: http://ir.epirusbiopharma.com/events.cfmPlease join the conference call at least 10 minutes early to register. The webcast will be archived on EPIRUS' website for a period of three months.

About EPIRUS BiopharmaceuticalsEPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS’ goal is to improve global patient access to important, cost-effective medicines.  EPIRUS' current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)[i]. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets. For more information visit EPIRUS’ website at www.epirusbiopharma.com.

Contact Information:For investor inquiries:Tom Shea, EPIRUS Biopharmaceuticals+1-617-600-3471tshea@epirusbiopharma.com

For media inquiries:Mike Devine, FleishmanHillard +1-212-453-2324 michael.devine@fleishman.com